GoldInxs Mining Corp. has closed the second tranche of its non-brokered private placement, raising a total of $1.25 million to fund exploration at its Fishpot Project in British Columbia. The company issued flow-through units and common shares with warrants, with proceeds earmarked for drilling and sampling. New directors Deepak Malhotra, Zoran Pudar, and Gordana Slepcev joined the board, bringing extensive mining experience. Additionally, GoldInxs made its first anniversary payment under the Fishpot option agreement and granted 1.5 million stock options to key personnel, signaling ongoing development and operational progress.
GoldInxs Mining Corp.'s recent private placement and board changes are noted here with Pluang's Basic Materials sector snapshot as of Oct 20, 2026 01:41 WIB. Among 83 priced US Basic Materials stocks on Pluang, 30 rose and 51 fell. Key movers include Gold Fields Limited (GFI) at USD 36.76 with a 1-day change of -2.23% and Pluang order activity of 17% Sell / 83% Buy, Nucor Corporation (NUE) at USD 261.96 with a 1-day change of +2.21% and 100% Sell order activity, and Gerdau S.A. (GGB) at USD 5.13 with a 1-day change of +2.19% and 100% Sell order activity. The most notable figure is GFI's 83% Buy order activity.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...
W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...
GE Aerospace is set to report its Q3 earnings with analysts forecasting a 21.7% rise in earnings per share to $2.02 and nearly 12% revenue growth to about $12.7 billion. Despite consistently beating estimates, the stock has fallen after past reports ...
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...
